Guardian Pharmacy Services (GRDN) Stock Price, News & Analysis

Company Overview

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

Key Stats

• Today's Range: $19.31 to $20.44
• 50-Day Range: $19.35 to $23.65
• 52-Week Range: $14.16 to $25.74
• Volume: 43,787 shs
• Average Volume: 51,354 shs
• Market Capitalization: $1.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

GRDN Stock Analysis - Frequently Asked Questions

How have GRDN shares performed this year?

Guardian Pharmacy Services' stock was trading at $20.26 on January 1st, 2025. Since then, GRDN stock has decreased by 3.4% and is now trading at $19.5750.
View the best growth stocks for 2025 here.

How were Guardian Pharmacy Services' earnings last quarter?

Guardian Pharmacy Services, Inc. (NYSE:GRDN) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($2.00) earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by $2.19. The company earned $314.39 million during the quarter, compared to analysts' expectations of $303.21 million.

When did Guardian Pharmacy Services IPO?

Guardian Pharmacy Services (GRDN) raised $102 million in an initial public offering (IPO) on Thursday, September 26th 2024. The company issued 6,800,000 shares at $14.00-$16.00 per share. Raymond James, Stifel and Truist Securities served as the underwriters for the IPO.

When does Guardian Pharmacy Services' lock-up period expire?

Guardian Pharmacy Services' lock-up period expires on Tuesday, March 25th. Guardian Pharmacy Services had issued 8,000,000 shares in its IPO on September 26th. The total size of the offering was $112,000,000 based on an initial share price of $14.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are Guardian Pharmacy Services' major shareholders?

Guardian Pharmacy Services' top institutional investors include Brown Advisory Inc. (2.52%), J. Goldman & Co LP (1.20%), Clearbridge Investments LLC (1.04%) and Nuveen Asset Management LLC (0.86%). Insiders that own company stock include Thomas J Salentine Jr and Steven D Cosler.
View institutional ownership trends.

How do I buy shares of Guardian Pharmacy Services?

Shares of GRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Guardian Pharmacy Services own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Guardian Pharmacy Services investors own include UnitedHealth Group (UNH) and Meta Platforms (META).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 2/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Drug stores & proprietary stores
• Sub-Industry: Retail
• Current Symbol: NYSE:GRDN
• Previous Symbol: NYSE:GRDN
• CUSIP: N/A
• CIK: 1802255
• Web: guardianpharmacy.com
• Phone: (404) 810-0089
• Fax: N/A
• Employees: 3,200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $22.00
• High Stock Price Target: $24.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +12.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 63,290,000
• Free Float: N/A
• Market Cap: $1.24 billion
• Optionable: N/A
• Beta: N/A